Molluscum contagiosum
diseaseOn this page
Summary
Molluscum contagiosum (MONDO:0005855) is a disease and 21 clinical trials. Top therapeutic interventions include berdazimer sodium, cantharidin, and acyclovir. A subtype of viral infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 21
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | molluscum contagiosum |
| Mondo ID | MONDO:0005855 |
| EFO | EFO:0007375 |
| MeSH | D008976 |
| DOID | DOID:8867 |
| ICD-10-CM | B08.1 |
| ICD-11 | 82201615 |
| SNOMED CT | 40070004 |
| UMLS | C0026393 |
| MedGen | 10081 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of viral infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › molluscum contagiosum
Related subtypes (40): Whitewater Arroyo hemorrhagic fever, exanthema subitum, Zika virus congenital syndrome, common wart, viral labyrinthitis, viral gastritis, vaccinia, viral esophagitis, Kaposi’s sarcoma, contagious pustular dermatitis, epidemic pleurodynia, herpangina, human T-lymphotropic virus 1 infectious disease, lumpy skin disease, milker’s nodule, Newcastle disease, pharyngoconjunctival fever, pseudorabies, Reoviridae infectious disease, immunodeficiency 32B, focal epithelial hyperplasia, neurolymphomatosis, viral myositis, virus-associated trichodysplasia spinulosa, infective dermatitis associated with HTLV-1, congenital varicella syndrome, viral hemorrhagic fever, arbovirus fever, human infection by orthopoxvirus, congenital Epstein-Barr virus infection, rabies, arbovirus infection, viral eye infection, viral infection of central nervous system, viral respiratory tract infection, Parvoviridae infectious disease, COVID-19–associated multisystem inflammatory syndrome in children, primary viral infectious disease, disease arising from reactivation of latent virus, human betaherpesvirus 5 infectious disease
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
2 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Berdazimer Sodium | Approved (phase 4) |
| Cantharidin | Approved (phase 4) |
| Adapalene | Phase 3 (in late-stage trials) |
| Benzoyl Peroxide | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Potassium Hydroxide.
Clinical trials & evidence
Clinical trials
Clinical trials: 21.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 7 |
| PHASE2 | 6 |
| Not specified | 4 |
| PHASE1 | 2 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01348386 | PHASE2/PHASE3 | COMPLETED | Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum |
| NCT03377790 | PHASE3 | COMPLETED | Cantharidin Application in Molluscum Patients-1 |
| NCT03377803 | PHASE3 | COMPLETED | Cantharidin Application in Molluscum Patients |
| NCT03927703 | PHASE3 | COMPLETED | A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC |
| NCT03927716 | PHASE3 | COMPLETED | A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1) |
| NCT04535531 | PHASE3 | COMPLETED | A Phase 3 Molluscum Contagiosum Efficacy and Safety Study |
| NCT05536882 | PHASE3 | WITHDRAWN | MC RCT - BPO vs Adapalene |
| NCT05937672 | PHASE3 | TERMINATED | Cold Atmospheric Plasma Device Extension Study |
| NCT02024581 | PHASE2 | TERMINATED | A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum |
| NCT02665260 | PHASE2 | COMPLETED | Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum |
| NCT03017846 | PHASE2 | COMPLETED | Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2 |
| NCT03077750 | PHASE2 | COMPLETED | A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum |
| NCT03186378 | PHASE2 | COMPLETED | Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. |
| NCT03436615 | PHASE2 | COMPLETED | A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum |
| NCT05634460 | PHASE1 | COMPLETED | Comparison of 5% Potassium Hydroxide With 10% Potassium Hydroxide Solution in Treatment of Molluscum Contagiosum |
| NCT05897112 | PHASE1 | COMPLETED | Comparative Efficacy of 10% Potassium Hydroxide Solution Versus Cryotherapy in Molluscum Contagiosum |
| NCT03336372 | EARLY_PHASE1 | WITHDRAWN | Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients |
| NCT02759900 | Not specified | UNKNOWN | Using a Cold Atmospheric Plasma Device to Treat Skin Disorders |
| NCT02902822 | Not specified | COMPLETED | Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo |
| NCT04476186 | Not specified | UNKNOWN | The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children |
| NCT05680181 | Not specified | COMPLETED | Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| BERDAZIMER SODIUM | 4 | 4 |
| CANTHARIDIN | 4 | 2 |
| ACYCLOVIR | 4 | 1 |
| BENZOYL PEROXIDE | 4 | 1 |
| INGENOL MEBUTATE | 4 | 1 |
| POTASSIUM | 3 | 1 |
| POTASSIUM HYDROXIDE | 3 | 1 |
| VEHICLE | 0 | 1 |